Breaking News
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Novartis Shareholders Approve All Board Resolutions, Chairman Vasella Steps Down

2/22/2013 10:14 AM ET

Swiss drug giant Novartis AG (NVS: Quote) announced Friday that the majority of its shareholders have approved all resolutions proposed and recommended by its board of directors at its annual general meeting held in Basel earlier in the day.

The company noted that 2688 shareholders attended the meeting, which represented about 1.66 billion shares or 61.5 percent, of the almost 2.71 billion issued shares of Novartis.

Among the proposals approved were a sixteenth consecutive dividend increase, election of Joerg Reinhardt to the Novartis board effective August 1, 2013 for a three year term, and the proposed changes in compensation system for the CEO and the members of the Executive Committee, effective January 1, 2014.

The company increased its annual dividend for 2012 by 2 percent to 2.30 Swiss francs per share, payable with effect from March 1, 2013. The dividend represents a payout ratio of about 65 percent of net income from continuing operations.

Meanwhile, Reinhardt was elected to the Novartis board effective August 1, 2013 for a three year term, and is also designated to become Chairman of the Board on that day. The current Chairman Daniel Vasella stepped down at the meeting, and current Vice Chairman Ulrich Lehner will serve as interim chairman until Reinhardt assumes office.

The Novartis board thanked Vasella for his services and dedication to the company for the last 25 years and for leading it as either CEO or Chairman over the last seventeen years. The board has decided to elect Vasella as Honorary Chairman of the Board as an honor for his accomplishments.

"After 25 years with the company, the time is right for me to ensure a smooth transition. Dr. Joerg Reinhardt is a very experienced healthcare executive with deep knowledge of the company and the industry, and shares a clear commitment to innovation. I wish him much success in this new role," Vasella said in a statement.

Further, the shareholders elected Verena Briner, Charles Sawyers and William Winter to the Novartis board for three-year terms.

Meanwhile, the shareholders also approved, in a consultative vote, the proposed changes to the Novartis compensation system for the CEO and the members of the executive committee, effective from January 1, 2014.

The new compensation system creates strong alignment with shareholder interests and allows them to better evaluate long and short-term performance relative to objectives of the CEO and members of the executive committee in order to foster long-term value creation.

During the Annual General Meeting, Novartis CEO Joseph Jimenez also renewed the company's commitment to its strategy and strategic priorities.

In Friday's regular trading session, NVS is currently trading at $68.77, up $0.05 or 0.07% on a volume of 0.14 million shares.

Register
To receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Russian Foreign Minister Sergei Lavrov warned Wednesday that Moscow would retaliate strongly if its "interests" in Ukraine are attacked. He also criticized the Ukrainian administration for relaunching its so-called anti-terrorist operation in the east of the country a day earlier. Lavrov's remarks came in an interview with Russia Today, which published excerpts of the English-language interview to While selling pressure has remained relatively subdued, stocks continue to see modest weakness in mid-day trading on Wednesday. The losses on the day come on the heels of the upward trend seen over the past several sessions. The major averages have moved roughly sideways in recent trading, lingering in the red. While a majority of Kentucky voters approve of the way Rand Paul is handling his job as Senator, the results of New York Times/Kaiser Family Foundation poll showed that voters from the Bluegrass State have a more mixed view on Paul's potential run for president in 2016.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.